CD69 and hepatocellular carcinoma: We demonstrate that Vγ9Vδ2 T-cells are selectively reduced in frequency in the blood, livers, and tumours of patients with HCC, but display the capacity to acquire an intratumoural γδ TRM (CD69+CD49a+ or CD69+CD103+) phenotype.